International certification-LUKAS BIOMEDICAL INC.

All certifications

Cutting-Edge Cancer Treatment Technologies

Lukas Biomedical's memory T cell culture technology has received exclusive authorization from Japan's National Cancer Center. It has completed Phase III clinical trials with Japan's Ministry of Health, Labour and Welfare, and successfully conducted Phase IV clinical trials in South Korea. The technology has obtained drug approval and is now marketed in South Korea, with over 10,000 clinical treatment cases recorded in Japan and South Korea. It has been proven to be a stable and effective method of immunotherapy for cancer treatment.

Establishing a technical collaboration with Japan's National Cancer Center and Lymphotec Inc.

In 2015, Lukas Biomedical invested and spent nearly two years to exclusively sign an agreement with Japan's Lymphotec Inc. for the 'Immune cell culture technology of activated lymphocyte therapy'. This technology has completed Phase III clinical trials in Japan and was transferred to South Korea, where it received marketing approval in 2016 under the product name 'Immuncell-LC'. At the present, nearly ten thousand clinical treatment cases related to this technology have been accumulated in Japan and South Korea.
Lukas Biomedical has transferred Japanese technology back to Taiwan, allowing cancer patients to receive top-tier cancer cell therapy domestically without having to travel abroad.

Note: Lymphotec Inc. of Japan was founded in 1999 by Dr. Teruaki Sekine, Principal Investigator of the National Cancer Center Research Institute.

The 4th Golden Ship Award for Innovative Services

In the 4th Golden Ship Award event organized by the General Chamber of Commerce of the Republic of China, Lukas Biomedical's exclusive Japanese technology, LuLym-T Cell Therapy, stood out among hundreds of companies and won the third place award in the highly competitive category, "Service Innovation".

Symbol of National Quality (SNQ) Mark certificate in 2023

Lukas Biomedical's "LuLym-T Cell Therapy" is an immunocellular cancer therapy technology based on autologous memory T cells. Objective data from clinical trials and international literature have demonstrated the long-term efficacy of memory T cells, especially in the treatment of solid tumors and the prevention of cancer recurrence. Lukas won the Symbol of National Quality (SNQ) Mark in the Medical Periphery Category/Cellular Therapy Group.

Recognized as one of the top 10 clinical trial biomedical companies in Asia by Life Sciences Review Magazine in 2023

Life Sciences Review is a U.S.-based business and technology magazine focused on the life sciences industry, publishing articles on advancements in science, technology, solutions, biology, and other fields.
Lukas Biomedical's clinical experience and maturity are highly recognized by international experts. The professional magazine formed a survey team, which first conducted an in-depth investigation by a professional team of doctors and experts, and recommended Lukas. After substantive interviews, Lukas entered the second round of selection. Finally, through a selection process and interviews with the management team, Lukas was selected as a finalist.

International Certifications

Lukas Biomedical's introduction of immunocellular therapy for cancer has been published in top international medical journals such as The Lancet (2000) and Gastroenterology (2015). The results of the Phase III clinical trials for liver cancer patients (n=150 and n=230) demonstrated that a single treatment course could effectively prolong recurrence-free survival time and increase overall survival rates.